Peter Turner

Peter Turner, President, CSL Behring; Chief Operating Officer, CSL Group; and Executive Director, CSL Board, has more than 40 years of experience in the biopharmaceutical industry. His expertise includes plasma fractionation, research and development, production, engineering and management. Mr. Turner contributed to the successful acquisition of Aventis Behring to form CSL Behring in 2004 and has served as President since that time.

Through his leadership, CSL Behring sales grew to $US2.98 billion for fiscal year 2009/10. He has also overseen the successful launch of several new products and brought a number of existing products into new markets.

Mr. Turner previously served as Chief Executive Officer and President of ZLB Bioplasma AG and ZLB Bioplasma Inc. (the ZLB Bioplasma Group) from July 2000 to March 2004. In this capacity, he was responsible for the integration of ZLB and Nabi Plasma Collection Centers into the CSL Group.

From 1996 to 2000, Mr. Turner served as General Manager of CSL Bioplasma Australia, a business unit of CSL. As General Manager, he was responsible for CSL’s plasma therapeutics business in Australia and neighboring countries. Previously, Mr. Turner served as Operations Manager and Plasma Products Project Director, roles that involved the development of CSL’s state-of-the-art plasma fractionation plant.

Mr. Turner has also served on the Board of Directors of the Plasma Protein Therapeutics Association, including four years as Chairman. He received B.Sc. degrees in chemistry, biochemistry and microbiology from the University of Melbourne and a MBA from the Royal Melbourne Institute of Technology.